First-in-human safety, imaging and dosimetry of [68Ga]Ga-DPI-4452, a novel CA IX-targeting peptide, in patients with clear cell renal cell carcinoma
Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC
Nephron Sparing Treatment (NEST) for small renal masses: A feasibility cohort-embedded randomised controlled trial comparing percutaneous cryoablation and robot-assisted partial nephrectomy
Development of a novel score (RENSAFE) to determine probability of acute kidney injury and renal functional decline post surgery: A multicenter analysis
Preoperative renal parenchyma volume as a predictor of kidney function following nephrectomy of complex renal masses
Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma
ESMO Congress 2023
Belzutifan versus everolimus in participants with previously treated advanced clear cell renal cell carcinoma: Randomized open-label phase III LITESPARK-005 study
Safety and efficacy of two doses of belzutifan in patients with advanced RCC: Results of the randomized phase II LITESPARK-013 study
Patient-reported outcome measurement and reporting for patients with advanced renal cell carcinoma: A systematic literature review
Multimodal recurrence scoring system for prediction of clear cell renal cell carcinoma outcome: a discovery and validation study
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
Risks and benefits of partial nephrectomy performed with limited or with zero ischaemia time
